Cutaneous Lupus Erythematosus (CLE) Overview

Save information for later
Sign Up

Learn About Cutaneous Lupus Erythematosus (CLE)

What is the definition of Cutaneous Lupus Erythematosus (CLE)?
Cutaneous lupus erythematosus is a skin condition that usually occurs in individuals with systemic lupus erythematosus (SLE) but may appear before the disease becomes systemic. Systemic lupus erythematosus is an autoimmune disease in which the immune system attacks the skin, joints, kidneys, brain, and other organs. Cutaneous lupus erythematosus is categorized into three types: chronic cutaneous lupus erythematosus (CCLE), also known as discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE), and acute cutaneous lupus erythematosus (ACLE).
What are the symptoms of Cutaneous Lupus Erythematosus (CLE)?
Symptoms of chronic cutaneous lupus erythematosus, also known as discoid lupus erythematosus, are the appearance of disc-like lesions on the skin that are thick, scaly, block hair follicles, appear on skin exposed to the sun, and cause scarring. Symptoms of subacute cutaneous lupus erythematosus are the appearance of thick, scaly lesions on the skin that do not scar. Symptoms of acute cutaneous lupus erythematosus are lesions on the skin that are triggered by sun exposure.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Cutaneous Lupus Erythematosus (CLE)?
Treatment for chronic cutaneous lupus erythematosus, also known as discoid lupus erythematosus, involves avoiding sun exposure; wearing Helioplex sunscreen with an SPF of 70 or higher; corticosteroid creams, ointments, and injections; anti-malarial medications, such as Plaquenil, hydroxychloroquine, or chloroquine; and/or immunosuppressive medications. Treatment for subacute cutaneous lupus erythematosus includes the use of sunscreen, wearing protective clothing when in the sun, and avoiding sun exposure. Subacute cutaneous lupus erythematosus is often resistant to treatment with steroids or anti-malarial medications. Acute cutaneous lupus erythematosus may be treated with prednisone or other immunosuppressive drugs, such as methotrexate, cyclosporine, azathioprine, or myco-phenolate mofetil.
Who are the top Cutaneous Lupus Erythematosus (CLE) Local Doctors?
Dr. Janiece R. Bridges
General Practice
Dr. Janiece R. Bridges
General Practice

Healing Arts Center L.L.C.

225 Violyn Dr, 
Branson, MO 
 (2.5 mi)
417-334-6660
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Janiece Bridges is a General Practice provider in Branson, Missouri. Dr. Bridges and is rated as an Experienced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). Her top areas of expertise are Glucocorticoid-Remediable Aldosteronism, Familial Hypertension, Hypertension, and Type 2 Diabetes (T2D). Dr. Bridges is currently accepting new patients.

Dr. Joseph L. Mayus
Rheumatology
Dr. Joseph L. Mayus
Rheumatology

Lester E Cox Medical Centers

1001 E Primrose St, 
Springfield, MO 
 (35.0 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Mayus is a Rheumatologist in Springfield, Missouri. Dr. Mayus and is rated as an Advanced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). His top areas of expertise are Fibromyalgia, Rheumatoid Arthritis (RA), Psoriasis, and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Dr. Mayus is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. Jo E. Feugate
Rheumatology
Dr. Jo E. Feugate
Rheumatology

Mercy Clinic Springfield Communities

940 W Mount Vernon St, 100 Mc Laboratory Services Nixa, 
Nixa, MO 
 (28.0 mi)
417-724-5220
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jo Feugate is a Rheumatologist in Nixa, Missouri. Dr. Feugate and is rated as an Experienced provider by MediFind in the treatment of Cutaneous Lupus Erythematosus (CLE). Her top areas of expertise are Rheumatoid Arthritis (RA), Sarcoidosis, Sjogren Syndrome, and Neurosarcoidosis. Dr. Feugate is currently accepting new patients.

View All Doctors
What are the latest Cutaneous Lupus Erythematosus (CLE) Clinical Trials?
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus With or Without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3

Summary: In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). The study will focus on participants who have either active subacute CLE or chronic CLE, or both. They may also have systemic lupus erythematosus (SLE). The participants did not respond to antimalarial therapy or had problems with the treatment that m...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Combination product, Other
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with cutaneous lupus erythematosus (CLE).

View All Clinical Trials